gemtuzumab ozogamicin
gemtuzumab ozogamicin: 7 clinical trials tracked.
gemtuzumab ozogamicin evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about gemtuzumab ozogamicin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 3 study sponsors
Related indications
Clinical Trials (7)
Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy
Primary endpoint: Complete remission without measurable residual disease (CRMRD-)
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Primary endpoint: Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Primary endpoint: Minimal residual disease (MRD)-negativity rate
A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
Primary endpoint: Maximum Tolerated Dose (MTD)
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML
Primary endpoint: Overall Survival (OS)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Primary endpoint: Event-free survival (EFS)
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy
Primary endpoint: Incidence of dose limiting toxicities (DLTs).